Browsing by Author "Yildiz, H."

Now showing 1 - 3 of 3

Could a New Measurement, a New Body Shape Index, Determine the Role of Obesity and Depression in Asthma Control
(Yuzuncu Yil Universitesi Tip Fakultesi, 2022) Çilingir, B.M.; Ekin, S.; Yildiz, H.; Sunnetcioglu, A.; Günbatar, H.
Obesity is common in asthma. Depression is thought to be one of the risk factors that increase obesi ty. It is known that depression has an effect on poor asthma control. Body Mass Index (BMI) is mostly used to define obesity. In recent years, however, the ‘A Body Shape Index’ (ABSI) based on waist circumference (WC) measurement has been developed and th e higher ABSI corresponds to a more central body volume concentration. Our aim was to examine the effect of obesity and depression on asthma control in a way that questions the usability of ABSI, which is new in abdominal obesity measurement. A total of 99 asthmatic patients aged between 18-80 years who were followed up in Chest Diseases outpatient clinics were included in the study. Demographic and medical history of the patients were recorded. Waist circumference /BMI2/3 X Length(m) 2/3 was calculated for ABSI measurement. Beck Depression Scale (BDS) and Asthma Control Test (ACT) were applied. Pulmonary Function Test was applied to all patients by the same trained person. Obese and morbidly obese patients had poor asthma control. We found that the presence of depression caused poor asthma control in all BMI groups. The poorly controlled asthma group and the obese and morbidly obese patients had higher depression scores. BMI and waist circumference were higher in the poorly controlled asthma group (p=0.002, 0.033 respectively). However, there was no significant difference between the asthma groups in terms of ABSI (p=0.529). The findings of this study indicate that depressive symptoms, increased BMI and WC were significantly associated with poor asthma control. But ABSI is no superior to BMI in detecting asthma control and depressive mood. However, we should prompt our patients to treatment and exercise, especially for abdominal obesity. We should recommend that asthma patients with depression consult a psychiatrist. In this way, we can control our asthma patients more effectively by minimizing the existing risks. © 2022, Yuzuncu Yil Universitesi Tip Fakultesi. All rights reserved.
Use of Abo Blood Groups and Co-Morbidities as Predictors of Mortality in Covid-19 Patients
(Verduci Editore s.r.l, 2022) Öncü, M.R.; Aktaş, R.S.; Gizli, G.; Bilvanisi, S.; Yildiz, H.; Baran, A.İ.
OBJECTIVE: This study aimed to investigate the mortality relationship between COVID-19 and ABO blood groups and comorbid diseases. The aim of this study was to determine whether ABO blood groups and comorbid diseases can be used as a prognostic factor for hospitalization. PATIENTS AND METHODS: This retrospective study included patients aged ≥ 18 years presenting to the adult emergency COVID-19 outpatient clinic. COVID-19 patients were divided into four stages according to their clinical status: mild, moderate, severe, and critical. Those with the comorbid disease were classified as Group I, and those without comorbid disease were classified as Group II. RESULTS: Of the 384 patients included in the study, 190 (49.5%) were male and 194 (50.5%) were female, with a mean age of 47.3 ± 18.4 years. The clinical data of the patients were scanned from the hospital automation system. Although the risk of transmission was higher, especially in people with A blood type, this rate was lower in the O blood group. The clinical course of the disease was more severe and the mortality rates were higher in the AB blood group (p < 0.001). In the hospital, 35 people who were treated for COVID-19 disease died. CONCLUSIONS: Certain ABO blood types and comorbid diseases were important risk factors for COVID-19 and were associated with mortality. We found that some ABO blood groups and comorbid diseases are associated with COVID-19 and may be important risk factors. While the risk of transmission of COVID-19 is high in blood group A, we think that the clinical course of COVID-19 may be more severe and the death rate higher in blood group AB. © 2022 Verduci Editore s.r.l. All rights reserved.
What Is the Case of More Accessibl E Treatment Options in Covid 19: Comparison of Hydroxychloroquine and Favipiravir Based on Laboratory Values
(Yuzuncu Yil Universitesi Tip Fakultesi, 2021) Çilingir, B.M.; Sunnetcioglu, A.; Yildiz, H.; Erçek, B.M.; Baykal, N.D.
Two of the drugs are frequently used in COVID-19 treatment algorithm because of their low cost, easy availabil ity and application; Hydroxychloroquine (HCQ) and Favipiravir. Our aim in this study is to compare the laboratory parameters of patients diagnosed with COVID-19 Pneumonia in whom HCQ and Favipiravir treatment was initiated, and to reveal the difference in the effectiveness of the treatments. 64 COVID-19 patients whose diagnoses were confirmed by real-time polymerase chain reaction test (RT-PCR) of nasopharyngeal swab samples and pneumonia image compatible with COVID-19 on Thorax CT were included in the study. Patients were divided into three groups: treated with HCQ, treated with favipiravir, and who were switched to favipiravir treatment when they did not benefit from HCQ. We compared the laboratory values on Day 1, Day 5 and at discharge. When compared in terms of laboratory values, there was no significant difference between the groups in which HCQ and Favipiravir was initiated. In the patient group who did not improve with HCQ and switched to favipiravi r treatment, lymphocyte levels increased and ferritin, CRP and d-dimer values decreased. The decrease in D-dimer and CRP values was statistically significant (p= 0.029, p= 0.048). PLT, Hemoglobin, RDW, MPV, NLR, PLR, INR values did not change significantly in any patient group. Our study with the most commonly used drugs in our country reveals that HCQ and Favipiravir are not superior to each other. When we changed the treatment with favipiravir in the group of patients receiving HCQ whose clinical an d / or laboratory values deteriorated, D-dimer and CRP values decreased during discharge. This finding shows how effective the timely treatment change is in the recovery of the patient by closely following the patient clinically and interpreting the laboratory values correctly. In COVID-19, we should direct the treatment of our patients by following the symptoms, risk factors and especially laboratory values. © 2021, Yuzuncu Yil Universitesi Tip Fakultesi. All rights reserved.